JSPR Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Wall Street analysts forecast JSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JSPR is12.00 USD with a low forecast of 4.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Jasper Therapeutics Inc revenue for the last quarter amounts to -19.17M USD, decreased -3.64

Jasper Therapeutics Inc. EPS for the last quarter amounts to -16999000.00 USD, increased 18.66

Jasper Therapeutics Inc (JSPR) has 64 emplpoyees as of March 31 2026.

Today JSPR has the market capitalization of 25.19M USD.